140 results
8-K
EX-10.1
avcn0i3vie41jletkho
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
S-8
1vwiponfq6
30 Nov 23
Registration of securities for employees
4:16pm
S-8
EX-5.1
2xn7 x9339qv1
30 Nov 23
Registration of securities for employees
4:16pm
S-8
9r0mn2pioguzc
30 Nov 23
Registration of securities for employees
4:16pm
8-K/A
EX-99.3
v8bosw9yunv 6215r
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-10.2
18oe6o6f2asr74z9 7n0
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
swx hto329valo6xp
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.4
7stk7
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
lbrab3 cvq9d8
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
ngghzrw6vphwwdg 8v47
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
u1a jq5vgimp67yr
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
0349grwpjh xj8
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-5.1
g7r5okajr bw8
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-99.3
mdx7j3u97ifz
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm